Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581155 | 0.86 | BCHE (0.57) | BCHECNR1KDRATMMCHR1 | |
| SCHEMBL4578784 | 0.85 | BCHE (0.45) | BCHEKDRATRATMMCHR1 | |
| SCHEMBL4578084 | 0.85 | BCHE (0.50) | BCHECNR1KDRATMABL1 | |
| SCHEMBL4580416 | 0.84 | BCHE (0.46) | BCHEKDRATMMCHR1ABL1 | |
| SCHEMBL4580365 | 0.84 | BCHE (0.45) | BCHESLC6A9ATMABL1BCR | |
| SCHEMBL4580170 | 0.83 | BCHE (0.43) | BCHEKDRATMMCHR1 | |
| SCHEMBL4579927 | 0.82 | BCHE (0.43) | BCHEKDRATMMCHR1ABL1 | |
| SCHEMBL4579400 | 0.82 | OXTR (0.47) | BCHEKDRATMMCHR1 | |
| SCHEMBL4579680 | 0.81 | BCHE (0.43) | BCHESLC6A9CNR1KDRATM | |
| SCHEMBL4578684 | 0.80 | CNR1 (0.42) | BCHECNR1KDRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | BCHE 2823/4885SLC6A9 4821/4885CNR1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.